课题基金 / 基金详情

项目摘要

项目成果

Shiqian Shen的其他基金

相似基金

相关文献

中文摘要
翻译
在高达26%的手术患者中,术后发生轻微但持续的学习和记忆缺陷, 称为术后认知功能障碍(POCD)。POCD已成为一个严重的公共卫生问题 因为它与更差的临床结果相关,包括死亡率增加。潜在的发病机制 POCD仍然不清楚。可改变和不可改变的因素都可能导致POCD。迄今为止, 关于POCD的研究主要集中在手术和麻醉对中枢神经系统的直接影响, 他们已经确定年龄和遗传是POCD的主要危险因素。不幸的是,这些是不可修改的 这些因素难以转化为临床治疗。因此,迫切需要确定 POCD潜在的可变因素。在许多可改变的因素中,饮食影响和肠道微生物群 与许多具有炎症特征的神经系统疾病有关。肠道微生物群是否 POCD的影响还有待研究。在我们的初步研究中,我们观察到一种以前未被认识到的 肠道菌群在小鼠股动脉吸入异氟烷后POCD发生中的作用 麻醉具体来说,我们发现:1)肠道菌群正常的小鼠不会发生POCD,而肠道菌群正常的小鼠不会发生POCD。 肠道菌群失调发展为POCD; 2)口服氨苄青霉素治疗导致肠道菌群失调状态,其特征为 肠道微生物群落结构变化和吲哚类化合物,特别是吲哚酚-3-硫酸盐的急剧减少 (IS)吲哚-3-丙酸(IPA)和吲哚-3-丙酸(IPA)对POCD有抑制作用 4)POCD小鼠显示氧化增加和线粒体功能受损, 海马,由活性氧(ROS)的产生增加建议,减少生产 的NADH,并降低蛋白质水平的NDUFS 4(一个关键的线粒体复合物I组成部分),当 与没有POCD的小鼠相比;和5)口服IPA减少ROS产生,增加 氨苄青霉素处理的小鼠海马中的NADH产生和NDUFS 4蛋白水平。基于这些 根据初步研究结果,我们假设肠道微生物群对POCD的发展有关键影响 通过IPA。在这项资助提出的研究计划中,我们将通过解决以下问题来检验这一假设: 三个关键问题:1)观察到的肠道生态失调对POCD的影响是一种附带现象还是一种偶然现象 “放任”效应?2)IPA在POCD中的保护作用的机制是什么?(3)我们可以 制定基于肠道微生物群和代谢物的策略来预防和治疗POCD?这笔赠款是建立在 我们新颖的初步发现和我们建立的研究平台, 宏基因组学和代谢组学与免疫学和神经行为测定。成功执行 这项建议将建立一个新的概念框架,将饮食和肠道等可变因素联系起来, 微生物群与POCD,并导致新的治疗策略。
英文摘要
In up to 26% surgical patients, subtle yet persistent deficits in learning and memory occur postoperatively, referred to as postoperative cognitive dysfunction (POCD). POCD has become a serious public health concern as it is associated with worse clinical outcomes including increased mortality. The pathogenesis underlying POCD remains unclear. Both modifiable and non-modifiable factors may contribute to POCD. To date, studies on POCD have primarily focused on direct influences of surgery and anesthesia on the central nervous system, which have identified age and genetics as major risk factors in POCD. Unfortunately, these are non-modifiable factors and difficult to be translated into clinical treatment. As such, there is an urgent need to identify modifiable factors underlying POCD. Among many modifiable factors, dietary influences and gut microbiota have been implicated in many neurological diseases with inflammatory features. Whether gut microbiota influences POCD has yet to be examined. In our preliminary studies, we observed a previously unrecognized role for gut microbiota in the development of POCD in mice post femoral artery exposure under isoflurane anesthesia. Specifically, we found: 1) mice with normal gut microbiota did not develop POCD while mice with gut dysbiosis developed POCD; 2) oral ampicillin treatment led to a status of gut dysbiosis, characterized by gut microbiota community structure changes and a dramatic decrease of indoles, particularly indoxyl-3-sulfate (IS) and indole-3-propionic acid (IPA); 3) oral administration of IPA, but not IS, deterred the POCD development; 4) mice with POCD displayed increased oxidation and impaired mitochondria function in the hippocampus, suggested by an enhanced production of reactive oxygen species (ROS), decreased production of NADH, and decreased protein levels of NDUFS4 (a critical mitochondria complex I component), when compared with mice without POCD; and 5) oral administration of IPA decreased ROS generation, increased NADH production and NDUFS4 protein levels in the hippocampus of ampicillin-treated mice. Based on these preliminary findings, we hypothesize that gut microbiota has a key influence on the development of POCD through IPA. In the research program proposed in this grant, we will examine the hypothesis by addressing three key questions: 1) Does the observed effect of gut dysbiosis on POCD represent an epiphenomenon or a ‘permissive’ effect? 2) What are the mechanisms underlying the IPA’s protective role in POCD? and 3) Can we develop a strategy based on gut microbiota and metabolites to prevent and treat POCD? This grant is built on our novel preliminary findings and our established research platform that combines cutting-edge metagenomics and metabolomics with immunological and neurobehavioral assays. Successful execution of this proposal will establish a novel conceptual framework linking modifiable factors such as diet and gut microbiota with POCD, and lead to new therapeutic strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gut Microbiota Underlies the Heterogeneity of Aging Brain's Susceptibility to Postoperative Delirium
  • 批准号:
    10297433
  • 项目类别:
  • 资助金额:
    $173.9万
  • 财政年份:
    2021
  • 负责人:
    Shiqian Shen
  • 依托单位:
Microbiome Dysbiosis and Postoperative Delirium Pathogenesis
  • 批准号:
    10055132
  • 项目类别:
  • 资助金额:
    $45.91万
  • 财政年份:
    2020
  • 负责人:
    Shiqian Shen
  • 依托单位:
Development and Validation of a Clinically Relevant Animal Pain Model
  • 批准号:
    10460795
  • 项目类别:
  • 资助金额:
    $38.86万
  • 财政年份:
    2020
  • 负责人:
    Shiqian Shen
  • 依托单位:
Aging Promotes Pain Chronification through Changes in PGC-1alpha Expression and Interneuron Dysfunction
  • 批准号:
    10250503
  • 项目类别:
  • 资助金额:
    $16.8万
  • 财政年份:
    2020
  • 负责人:
    Shiqian Shen
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: